Use of genetically engineered antibodies to cd38 to treat...

Details Use of genetically engineered antibodies to cd38 to treat... Use of genetically engineered antibodies to cd38 to treat...

A - Human Necessities

61

K

A61K 31/70 (2006.01) A61K 38/16 (2006.01) A61K 39/395 (2006.01) A61K 47/48 (2006.01) C07K 14/46 (2006.01) C07K 16/28 (2006.01) C07K 19/00 (2006.01) C12N 15/31 (2006.01) C12N 15/62 (2006.01) A61K 38/00 (2006.01)

Patent

CA 2329940

A fusion polypeptide comprising an antibody or a fragment thereof is provided. The fusion polypeptide is useful in a therapeutic composition to treat multiple myeloma.

La présente invention concerne un polypeptide de fusion renfermant un anticorps ou un fragment de cet anticorps. Ce polypeptide de fusion joue un rôle utile dans des compositions pharmaceutiques destinées au traitement du myélome multiple.

Affiliated with

Also associated with

Rating

Use of genetically engineered antibodies to cd38 to treat... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Use of genetically engineered antibodies to cd38 to treat..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of genetically engineered antibodies to cd38 to treat... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFCA-PAI-O-1726409